We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The expanded approval is for patients who are at least 13 years old who cannot be effectively treated with continuous positive airway pressure (CPAP) therapy. Read More
The FDA said it could not approve AbbVie’s new drug application (NDA) for ABBV-951 (foslevodopa/foscarbidopa), an investigational therapy for advanced Parkinson’s disease, because of concerns about the delivery device. Read More
The Centers for Medicare and Medicaid Services (CMS) has given Applied VR a unique payment code — the first for a virtual reality (VR) device — for its RelieVRx, providing a pathway for Medicare and Medicaid to cover the device as durable medical equipment (DME).